Iron homeostasis and pulmonary hypertension: Iron deficiency leads to pulmonary vascular remodeling in the rat

Circulation Research

Volumn 116, Issue 10, 2015, Pages 1680-1690

  Cotroneo, Emanuele ^a   Ashek, Ali ^a   Wang, Lei ^a   Wharton, John ^a   Dubois, Olivier ^a   Bozorgi, Sophie ^a   Busbridge, Mark ^c   Alavian, Kambiz N ^b   Wilkins, Martin R ^a   Zhao, Lan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Glycolysis; Hypertension, pulmonary; Iron; STAT3; Vascular remodeling

Indexed keywords

DICHLOROACETIC ACID; FERRIC CARBOXYMALTOSE; FERRITIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; HEXOKINASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMATINIB; IRON; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR NFAT; TRANSFERRIN; ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; BENZAMIDE DERIVATIVE; FERRIC ION; MALTOSE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMICAL ANALYSIS; CARDIOPULMONARY HEMODYNAMICS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEART MITOCHONDRION; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART RIGHT VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; HUMAN CELL; INFLAMMATORY CELL; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON HOMEOSTASIS; IRON STORAGE; IRON THERAPY; LIVER; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; TRANSFERRIN BLOOD LEVEL; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; ANALOGS AND DERIVATIVES; ANIMAL; ARTERIAL PRESSURE; BLOOD; COMPLICATION; DEFICIENCY; DEFICIENCY DISEASES; DISEASE MODEL; DRUG EFFECTS; GLYCOLYSIS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BENZAMIDES; CELL PROLIFERATION; DEFICIENCY DISEASES; DICHLOROACETIC ACID; DISEASE MODELS, ANIMAL; ERYTHROPOIESIS; FERRIC COMPOUNDS; FERRITINS; GLYCOLYSIS; HEMATINICS; HOMEOSTASIS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IRON; LIVER; MALE; MALTOSE; PIPERAZINES; PULMONARY ARTERY; PYRIMIDINES; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFERRIN; VASCULAR REMODELING;

EID: 84934945418     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.305265     Document Type: Article

References (50)

1. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA., The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008; 586: 5999-6005. doi: 10.1113/jphysiol.2008.160960
2. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, León-Velarde F, Robbins PA., Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 2009; 302: 1444-1450. doi: 10.1001/jama.2009.1404
3. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, Wharton J, Wilkins MR., Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011 58 300 309
4. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A., Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011; 37: 1386-1391. doi: 10.1183/09031936.00100510
5. Soon E, Treacy CM, Toshner MR, MacKenzie-Ross R, Manglam V, Busbridge M, Sinclair-McGarvie M, Arnold J, Sheares KK, Morrell NW, Pepke-Zaba J., Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011; 66: 326-332. doi: 10.1136/thx.2010.147272
6. van Empel VP, Lee J, Williams TJ, Kaye DM., Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ 2014; 23: 287-292. doi: 10.1016/j.hlc.2013.08.007
7. Howard LS, Watson GM, Wharton J, Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ 2013; 3: 100-107. doi: 10.4103/2045-8932.109923
8. Robinson JC, Graham BB, Rouault TC, Tuder RM., The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol 2014; 51: 721-729. doi: 10.1165/rcmb.2014-0021TR
9. Naito Y, Hosokawa M, Hao H, Sawada H, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Hirota S, Ohyanagi M, Tsujino T, Masuyama T., Impact of dietary iron restriction on the development of monocrotaline-induced pulmonary vascular remodeling and right ventricular failure in rats. Biochem Biophys Res Commun 2013; 436: 145-151. doi: 10.1016/j.bbrc.2013.05.059
10. Wong CM, Preston IR, Hill NS, Suzuki YJ., Iron chelation inhibits the development of pulmonary vascular remodeling. Free Radic Biol Med 2012; 53: 1738-1747. doi: 10.1016/j.freeradbiomed.2012.08.576
11. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F., Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821. doi: 10.1172/JCI24838
12. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL., Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002 105 244 250
13. Lemson J, de Boode WP, Hopman JC, Singh SK, van der Hoeven JG., Validation of transpulmonary thermodilution cardiac output measurement in a pediatric animal model. Pediatr Crit Care Med 2008; 9: 313-319. doi: 10.1097/PCC.0b013e31816c6fa1
14. Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, Howard LS, Gibbs JS, Gsell W, He JG, Wilkins MR., Heterogeneity in lung 18FDG uptake in pulmonary arterial hypertension: potential of dynamic 18FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 2013 128 1214 1224
15. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M., The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977 28 897 916
16. Savai R, Pullamsetti SS, Kolbe J, Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 897-908. doi: 10.1164/rccm.201202-0335OC
17. Medeiros DM, Beard JL., Dietary iron deficiency results in cardiac eccentric hypertrophy in rats. Proc Soc Exp Biol Med 1998 218 370 375
18. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P., Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 2003; 111: 1519-1527. doi: 10.1172/JCI15496
19. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL., Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999; 103: 691-696. doi: 10.1172/JCI5912
20. Brooks GA, Henderson SA, Dallman PR., Increased glucose dependence in resting, iron-deficient rats. Am J Physiol 1987 253 E461 E466
21. Henderson SA, Dallman PR, Brooks GA., Glucose turnover and oxidation are increased in the iron-deficient anemic rat. Am J Physiol 1986 250 E414 E421
22. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED., The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007; 104: 11418-11423. doi: 10.1073/pnas.0610467104
23. Paulin R, Meloche J, Bonnet S., STAT3 signaling in pulmonary arterial hypertension. JAKSTAT 2012; 1: 223-233. doi: 10.4161/jkst.22366
24. Paulin R, Michelakis ED., The metabolic theory of pulmonary arterial hypertension. Circ Res 2014; 115: 148-164. doi: 10.1161/CIRCRESAHA.115.301130
25. Alavian KN, Dworetzky SI, Bonanni L, Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 2012; 1446: 1-11. doi: 10.1016/j.brainres.2012.01.046
26. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznerski P, Li H, Nabili P, Hockensmith K, Graham M, Porter GA Jr, Jonas EA., An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci U S A 2014; 111: 10580-10585. doi: 10.1073/pnas.1401591111
27. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED., Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005; 115: 1479-1491. doi: 10.1172/JCI23203
28. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I., Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 2008; 109: 394-402. doi: 10.1016/j.ygyno.2008.01.038
29. Bernardo PS, Reis FR, Maia RC., Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells. Leuk Res 2012; 36: 1510-1516. doi: 10.1016/j.leukres.2012.08.014
30. Ma H, Nguyen C, Lee KS, Kahn M., Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005; 24: 3619-3631. doi: 10.1038/sj.onc.1208433
31. Borel MJ, Smith SH, Brigham DE, Beard JL., The impact of varying degrees of iron nutriture on several functional consequences of iron deficiency in rats. J Nutr 1991 121 729 736
32. Chen OS, Schalinske KL, Eisenstein RS., Dietary iron intake modulates the activity of iron regulatory proteins and the abundance of ferritin and mitochondrial aconitase in rat liver. J Nutr 1997 127 238 248
33. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J., Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005; 109: 277-286. doi: 10.1042/CS20040278
34. Pietra GG., Histopathology of primary pulmonary hypertension. Chest 1994 105 2S 6S
35. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM., Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004 43 25S 32S. doi: 10.1016/j.jacc.2004.02.033
36. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM., Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261-272. doi: 10.1164/rccm.201201-0164OC
37. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S., Pathology of pulmonary hypertension. Clin Chest.Med 2007 28 23 42, vii. doi: 10.1016/j.ccm.2006.11.010
38. Tuder RM., Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 376-385. doi: 10.1055/s-0029-1233307
39. Semenza GL., Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399-408. doi: 10.1016/j.cell.2012.01.021
40. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT., Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 1998 95 11715 11720
41. Hickey MM, Richardson T, Wang T, Mosqueira M, Arguiri E, Yu H, Yu QC, Solomides CC, Morrisey EE, Khurana TS, Christofidou-Solomidou M, Simon MC., The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest 2010; 120: 827-839. doi: 10.1172/JCI36362
42. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, Archer SL., An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006; 113: 2630-2641. doi: 10.1161/CIRCULATIONAHA.105.609008
43. Pagani A, Nai A, Corna G, Bosurgi L, Rovere-Querini P, Camaschella C, Silvestri L., Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood 2011; 118: 736-746. doi: 10.1182/blood-2011-02-337212
44. Anker SD, Comin Colet J, Filippatos G, FAIR-HF Trial Investigators Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448. doi: 10.1056/NEJMoa0908355
45. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P., Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-112. doi: 10.1016/j.jacc.2007.09.036
46. Michelakis ED, Webster L, Mackey JR., Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-994. doi: 10.1038/sj.bjc.6604554
47. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ., Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004; 10: 6661-6668. doi: 10.1158/1078-0432.CCR-04-0039
48. Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, Prchal JT, Ge R., Genetic evidence for high-altitude adaptation in Tibet. Science 2010; 329: 72-75. doi: 10.1126/science.1189406
49. West JB., High-altitude medicine. Am J Respir Crit Care Med 2012; 186: 1229-1237. doi: 10.1164/rccm.201207-1323CI
50. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P., Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816-829. doi: 10.1093/eurheartj/ehs224